Vaccine
development
service

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

• Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
• ALS vaccine is targeting the most common genetic ALS variant
• 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced…

• Publication annual report 2021
• Appointment of a Chief Business Officer
• Appointment of a Director vaccine process development
• Chief Financial Officer joins the Board of Directors

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

• Avacc 3 has significant advantages over existing whooping cough vaccines
• Second major OMV platform licensing agreement with pharmaceutical company
• Over 24 million cases of whooping cough per year world-wide